Lakshmana Pendyala
Overview
Explore the profile of Lakshmana Pendyala including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
219
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Magalhaes M, Minha S, Lhermusier T, Pendyala L, Escarcega R, Baker N, et al.
Catheter Cardiovasc Interv
. 2016 Nov;
90(2):213-222.
PMID: 27862877
Objectives: The aim of this study is to summarize the outcomes of patients undergoing direct stenting (DS) with drug-eluting stents (DES) compared to those who underwent balloon predilatation. Background: DS...
2.
Pendyala L, Loh J, Kitabata H, Minha S, Chen F, Torguson R, et al.
J Invasive Cardiol
. 2015 Jun;
27(6):263-8.
PMID: 26028652
Objectives: This study aimed to evaluate the safety and efficacy of everolimus-eluting stent (EES) use compared with first-generation drug-eluting stent (DES) use in diabetic patients undergoing multivessel percutaneous coronary intervention...
3.
Lhermusier T, Lipinski M, Tantry U, Escarcega R, Baker N, Bliden K, et al.
Am J Cardiol
. 2015 Mar;
115(6):716-23.
PMID: 25728845
Studies have linked on-treatment platelet reactivity (PR) to adverse clinical outcomes. Because new P2Y12 inhibitors (prasugrel and ticagrelor) have been predominantly tested against clopidogrel, data on pharmacodynamic comparisons between these...
4.
Superko H, Pendyala L, Williams P, Momary K, King 3rd S, Garrett B
J Clin Lipidol
. 2013 Jan;
6(6):496-523.
PMID: 23312047
Objective: To assess the clinical utility of measuring high-density lipoprotein (HDL) subfractions to assess coronary heart disease (CHD) risk. Methods: Literature review of 80 published investigations. Results: Measurements of HDL2b...
5.
Jabara R, Pendyala L, Geva S, Chen J, Chronos N, Robinson K
EuroIntervention
. 2011 Nov;
5 Suppl F:F58-64.
PMID: 22100678
Aims: The concept of fully biodegradable stents has emerged as an attractive alternative to current permanent metallic stents, mainly as a potential solution to avoid late stent thrombotic events. We...
6.
Williams P, Pendyala L, Superko R
BMC Med Genet
. 2011 Mar;
12:42.
PMID: 21435211
Background: Case-control studies typically exclude fatal endpoints from the case set, which we hypothesize will substantially underestimate risk if survival is genotype-dependent. The loss of fatal cases is particularly nontrivial...
7.
Zhang G, Yin X, Qi Y, Pendyala L, Chen J, Hou D, et al.
Curr Cardiol Rev
. 2011 Feb;
6(1):62-70.
PMID: 21286280
Ghrelin, a newly discovered bioactive peptide, is a natural endogenous ligand of the growth hormone (GH) secretagogue receptor and initially identified as a strong stimulant for the release of GH....
8.
Superko H, Roberts R, Garrett B, Pendyala L, King 3rd S
Clin Cardiol
. 2010 Dec;
33(12):E1-6.
PMID: 21184539
A family history of coronary heart disease (CHD) is an accepted risk factor for cardiovascular events and is independent of common CHD risk factors. Advances in the understanding of genetic...
9.
Pendyala L, Yin X, Li J, Shinke T, Xu Y, Chen J, et al.
EuroIntervention
. 2010 Jun;
6(1):126-33.
PMID: 20542808
Aims: The present study was designed to evaluate vasomotor function and vascular biological responses following a novel non-polymeric cerivastatin-eluting stent (CES) versus polymer-based paclitaxel-eluting stent (PES) in a rabbit iliac...
10.
Shinke T, Li J, Chen J, Pendyala L, Goodchild T, Jabara R, et al.
Circ Cardiovasc Interv
. 2009 Dec;
1(1):28-35.
PMID: 20031652
Background: Systematic analysis of in vivo angioscopy and postmortem histopathology for paclitaxel-eluting stents (PES) has not been previously reported. We assessed 1-month angioscopic and histopathologic sequelae of overlapping PES in...